AU2001228703A1 - Use of cox-2 inhibitors for the treatment of constipation - Google Patents

Use of cox-2 inhibitors for the treatment of constipation

Info

Publication number
AU2001228703A1
AU2001228703A1 AU2001228703A AU2870301A AU2001228703A1 AU 2001228703 A1 AU2001228703 A1 AU 2001228703A1 AU 2001228703 A AU2001228703 A AU 2001228703A AU 2870301 A AU2870301 A AU 2870301A AU 2001228703 A1 AU2001228703 A1 AU 2001228703A1
Authority
AU
Australia
Prior art keywords
constipation
cox
inhibitors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228703A
Inventor
Allen Wayne Mangel
Alan Naylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001228703A1 publication Critical patent/AU2001228703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AU2001228703A 2000-02-01 2001-02-01 Use of cox-2 inhibitors for the treatment of constipation Abandoned AU2001228703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002312.7 2000-02-01
GBGB0002312.7A GB0002312D0 (en) 2000-02-01 2000-02-01 Medicaments
PCT/GB2001/000416 WO2001056555A2 (en) 2000-02-01 2001-02-01 Use of cox-2 inhibitors for the treatment of constipation

Publications (1)

Publication Number Publication Date
AU2001228703A1 true AU2001228703A1 (en) 2001-08-14

Family

ID=9884766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228703A Abandoned AU2001228703A1 (en) 2000-02-01 2001-02-01 Use of cox-2 inhibitors for the treatment of constipation

Country Status (6)

Country Link
US (1) US20030013717A1 (en)
EP (1) EP1251839A2 (en)
JP (1) JP2003521511A (en)
AU (1) AU2001228703A1 (en)
GB (1) GB0002312D0 (en)
WO (1) WO2001056555A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0119477D0 (en) * 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
AU2003248642A1 (en) 2002-06-11 2003-12-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
ES2263058T3 (en) * 2002-08-19 2006-12-01 Glaxo Group Limited PIRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS.
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
EP1514482B2 (en) * 2003-09-12 2016-06-22 Nestec S.A. Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases
ES2655030T3 (en) 2012-11-19 2018-02-16 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
RU2690188C2 (en) * 2017-05-26 2019-05-31 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" New multitarget preparation for treating diseases in mammals
JP7195067B2 (en) * 2018-06-20 2022-12-23 花王株式会社 Rosmarinic acid derivative or its salt
JP7223477B2 (en) * 2018-10-10 2023-02-16 花王株式会社 TRPV4 activity inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001111A1 (en) * 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139638A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
NZ304886A (en) * 1995-04-04 1998-11-25 Glaxo Group Ltd Imidazo [1,2a] pyridine derivatives, preparation and pharmaceutical compositions thereof
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
GB9709739D0 (en) * 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation
AU744997B2 (en) * 1997-09-05 2002-03-07 Glaxo Group Limited 2,3-diaryl-pyrazolo(1,5-B)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US5929035A (en) * 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
DE69919887T2 (en) * 1998-11-03 2005-09-15 Glaxo Group Ltd., Greenford PYRAZOLOPYRIDINE DERIVATIVE AS SELECTIVE COX-2 INHIBITORS
US6444198B1 (en) * 1999-02-22 2002-09-03 Smithkline Beecham Corporation Effervescent laxatives
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
WO2001056555A2 (en) 2001-08-09
EP1251839A2 (en) 2002-10-30
GB0002312D0 (en) 2000-03-22
US20030013717A1 (en) 2003-01-16
WO2001056555A3 (en) 2002-08-08
JP2003521511A (en) 2003-07-15

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
GB0025782D0 (en) Use of inhibitors
AU2001272852A1 (en) Composition for the treatment of migraine
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
MXPA03000694A (en) New use of lipase inhibitors.
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AP2003002719A0 (en) Use of cox-2 inhibitors for preventing immunodeficiency
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU2001285156A1 (en) Combination therapy for the treatment of migraine
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001268236A1 (en) Use of aicar and related compounds
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001251004A1 (en) Detection of viable agents
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2001281465A1 (en) Treatment of rosacea
AU6947900A (en) Methods of use of fluoroquinolone compounds against bacteria
AU7709400A (en) Methods of use of fluoroquinolone compounds against bacteria
AU2002305868A1 (en) Inhibitors of reggamma